Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RxHub formulary transfer protocol (correction)

Executive Summary

RxHub's formulary and benefit file transfer protocol is based on proprietary technology. The protocol is the basis for a National Council for Prescription Drug Programs standard currently in development which will be made public as a standardized formulary and benefit transfer protocol. "The Pink Sheet" incorrectly reported that RxHub's protocol is based on the Veterans Administrations' National Drug File-Reference Terminology (1"The Pink Sheet" Sept. 6, 2004, p. 16). RxHub uses National Drug Classification codes to identify particular products within the formulary. The National Committee on Vital & Health Statistics recommended that FDA incorporate the VA's classification into structured product labels, which map NDC codes to RxNorm, the electronic prescribing standard...

You may also be interested in...

FDA Enters Formulary Fray: Agency Plans Analysis For E-Rx Standards

FDA will submit comments to HHS analyzing the U.S. Pharmacopoeia draft Medicare formulary guidelines and the Veterans Administration drug classification for compatibility with electronic prescribing platforms

Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO

The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts